Sort by Year:
Sort by Division:
07/29/15
Par Pharmaceutical Begins Shipment of Generic Megace® ES
05/27/15
Par Pharmaceutical Receives Favorable Appeals Court Ruling in Generic Exelon® Patch Litigation
05/26/15
Par Specialty Pharmaceuticals Launches Cortisporin®-TC Otic Suspension
05/18/15
Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader
05/07/15
Par Pharmaceutical Announces First Quarter 2015 Conference Call
03/30/15
Par Specialty Pharmaceuticals Launches Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device Along with Nascobal® Nutrition Direct™ Program
03/13/15
Par Pharmaceutical Files Registration Statement for Initial Public Offering
03/05/15
Par Pharmaceutical Announces Fourth-Quarter and Full-Year 2014
11/12/14
Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP)
11/05/14
Par Pharmaceutical Announces Quarterly Conference Call
09/30/14
Par Pharmaceutical Begins Shipment of Generic Exforge®
09/08/14
Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection
08/06/14
Par Pharmaceutical Announces Quarterly Conference Call
07/09/14
Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP
06/10/14
Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device
05/28/14
Par Pharmaceutical Statement on Brevital® Sodium
05/07/14
Par Pharmaceutical Announces Quarterly Conference Call
04/07/14
Par Pharmaceutical Begins Shipment of Potassium Chloride Extended-Release Capsules
04/01/14
Par Pharmaceutical Names Terrance J. Coughlin Chief Operating Officer
03/13/14
Par Pharmaceutical Announces Fourth Quarter and Full Year 2013 Conference Call
02/20/14
Par Pharmaceutical Names Antonio R. Pera Chief Commercial Officer
01/21/14
Par Pharmaceutical to Acquire JHP Pharmaceuticals
01/16/14
Par Pharmaceutical Begins Shipment of Generic Lanoxin®
11/20/13
Par Pharmaceutical Begins Shipment of Generic Focalin XR® Capsules
 First | Previous | Next | Last